Extended Data Fig. 7: Neutralization assays and ACE2 competition assays for anti-RBD nanobodies evolved with AHEAD. | Nature Chemical Biology

Extended Data Fig. 7: Neutralization assays and ACE2 competition assays for anti-RBD nanobodies evolved with AHEAD.

From: Rapid generation of potent antibodies by autonomous hypermutation in yeast

Extended Data Fig. 7

a, Neutralization plots for all anti-RBD nanobodies characterized in this study. Each nanobody concentration (X-axis) was tested in replicate. n = 6, error bars represent ± s.d. b, Biolayer interferometry (BLI) traces measuring ACE2 competition for anti-RBD nanobodies. CR3022 is an anti-RBD antibody that does not compete with ACE2 binding (no competition control) whereas SC1A-B12 is an anti-RBD antibody that competes strongly with RBD binding.

Back to article page